Multidisciplinary

Cranberry juice a potential treatment for H pylori infection?

Pearl Toh, 9 hours ago

Consuming cranberry juice twice daily for 8 weeks can help suppress Helicobacter (H.) pylori infection among Chinese adults, suggests a randomized study — thus opening the door to using cranberry juice as a complementary approach to H. pylori management.

Novel monoclonal antibody shows promise against moderate to severe AD

14 hours ago

A phase I, single-centre, open-label study has found that repeated intravenous infusions of KHK4083, an investigational human monoclonal antibody, is sufficiently safe and clinically effective for the treatment of moderate to severe atopic dermatitis (AD).

Mepolizumab: Targeting eosinophils in severe asthma with precision medicine

Pearl Toh, 16 Sep 2020

Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.

Novel drug delivery system reduces treatment burden in neovascular AMD

Dr. David Eichenbaum, Dr. Dilsher Dhoot, Prof. Peter Campochiaro, Dr. Timothy Y Y Lai, 04 Sep 2020

Intravitreal injection of antiangiogenic agents is the standard of care for neovascular age-related macular degeneration (nAMD), however, frequent injections represent a considerable treatment burden for patients. Results of the Ladder and Archway studies, presented at the 38th Annual Meeting of the American Society of Retina Specialists (ASRS 2020), showed that administration of ranibizumab through a port delivery system (PDS) considerably reduced treatment burden, while maintaining comparable efficacy and safety vs intravitreal injections. In an interview with MIMS Doctor, Dr Timothy Lai of Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, discusses how PDS may transform the management of nAMD.

NCDs continue with march in the shadow of COVID-19

Pank Jit Sin, 02 Sep 2020

The most recent report by the National Health and Morbidity Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with consistent, unrelenting efforts by stakeholders and policymakers, the figures for NCDs continue to climb. MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in the country and to obtain his thoughts on the ramifications of the findings.

First-line triple combo therapy shows potential in PAH

Roshini Claire Anthony, 18 Sep 2020

Adding selexipag to the double combination therapy of macitentan and tadalafil (triple combination) improved multiple outcomes in patients newly diagnosed with pulmonary arterial hypertension (PAH), results of the phase IIIb TRITON* trial showed.

Gefapixant cuts frequency of chronic coughs in 2 large studies

Pearl Toh, 18 Sep 2020

Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.

Wearable system monitors respiratory pattern, thoracic motion on tablet PC

Stephen Padilla, 18 Sep 2020

A newly developed mobile wearable system promises to deliver accurate real-time assessment of respiratory pattern and thoracic motion noninvasively, according to a feasibility study in Japan.

Add-on mepolizumab reduces nasal polyp size, obstruction in adults with CRSwNP

Elaine Soliven, 18 Sep 2020

Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.

Can riociguat REPLACE PDE-5is for PAH?

Audrey Abella, 17 Sep 2020

Patients with pulmonary arterial hypertension (PAH) experienced clinical improvement when they switched from a phosphodiesterase type 5 inhibitor (PDE-5i) to riociguat, highlighting the latter’s potential as a treatment alternative in this setting, results of the REPLACE* study have shown.

Mepolizumab: Targeting eosinophils in severe asthma with precision medicine

Pearl Toh, 16 Sep 2020

Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!